無料セミナー : 2018年10月2日『プレシジョン・メディシンの戦略的分析、将来動向予測』 BIS Research共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオマーカーの世界市場予測 2017-2027年:バイオマーカーサービス、バイオマーカー診断、バイオマーカー創薬、ゲノミクス、プロテオミクス、バイオインフォマティクス

Global Biomarkers Market Forecast 2017-2027: Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases

発行 Visiongain Ltd 商品コード 206674
出版日 ページ情報 英文 206 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=152.26円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
バイオマーカーの世界市場予測 2017-2027年:バイオマーカーサービス、バイオマーカー診断、バイオマーカー創薬、ゲノミクス、プロテオミクス、バイオインフォマティクス Global Biomarkers Market Forecast 2017-2027: Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases
出版日: 2017年10月18日 ページ情報: 英文 206 Pages
概要

世界のバイオマーカー市場規模は、予測期間の前半に9.1%のCAGR (年間複合成長率) で拡大すると予測されています。2016年の同市場における最大部門はバイオマーカー創薬となり、世界のバイオマーカー市場の49.3%を構成しました。

当レポートでは、世界のバイオマーカー市場について調査し、市場の概要、部門、領域、適応症、および地域別による市場収益予測、定性分析 (SWOT・STEP) 、および主要企業のプロファイルなどをまとめています。

第1章 調査概要

第2章 バイオマーカーのイントロダクション

  • バイオマーカーの定義
    • バイオマーカーの略歴
    • バイオマーカーの重要性
  • バイオマーカーの創薬および検証
  • バイオマーカーの利用
    • 医薬品有効性の評価
    • 医薬品安全性の評価
    • コンパニオン診断
    • バイオマーカーの治療上の重要性
    • イメージングバイオマーカー
  • バイオマーカーおよび個別化医療
  • バイオマーカー創薬
    • ゲノミクス
    • プロテオミクス
    • メタボロミクス

第3章 世界のバイオマーカー市場

  • 世界のバイオマーカー市場
  • 世界のバイオマーカー市場:全体的な収益の予測
  • 世界のバイオマーカー創薬のサブマーケット
  • 世界のバイオマーカー診断のサブマーケット
  • 世界のバイオマーカーサービスのサブマーケット
  • 世界のバイオマーカー市場:全体的な収益予測、領域別
  • 主なバイオマーカー分野の成長

第4章 バイオマーカー創薬・開発の主な適応症

  • 世界のバイオマーカー市場:適応症別
    • バイオマーカーのクラス
    • 薬力学バイオマーカー
  • 世界のバイオマーカー市場:適応症別の収益予測
  • 世界のバイオマーカー市場予測:適応症別
  • 癌バイオマーカー市場
  • 心臓病バイオマーカーサブマーケット
  • CNS (中枢神経系) 疾患バイオマーカーサブマーケット
  • 自己免疫疾患バイオマーカーサブマーケット
  • 主なバイオマーカー適応症における成長

第5章 主要国のバイオマーカー市場

  • 世界のバイオマーカー市場:地域別分析
  • 世界のバイオマーカー市場:地域別予測
  • 米国のバイオマーカー市場
  • EU5ヶ国のバイオマーカー市場
  • 日本のバイオマーカー市場
  • 中国のバイオマーカー市場
  • インドのバイオマーカー市場
  • ロシアのバイオマーカー市場
  • ブラジルのバイオマーカー市場
  • その他 (RoW) のバイオマーカー市場

第6章 バイオマーカー産業の動向

  • バイオマーカー市場の強みと弱み
  • バイオマーカー市場の機会と脅威
  • 世界のバイオマーカー市場:STEP分析
  • 社会的要因
  • 技術的要因
  • 経済的要因
  • 政治的要因
  • 開発中のバイオマーカーにおける課題
  • 混合薬・診断の発展
  • マイクロRNAバイオマーカー
  • 大手製薬企業とバイオマーカー

第7章 バイオマーカー市場の主要企業

  • バイオマーカーサービスプロバイダー
  • バイオマーカー技術プロバイダー
  • バイオマーカー診断ディベロッパー

第8章 結論

  • 世界のバイオマーカー市場の状況
  • 世界のバイオマーカー市場における成長
  • 創薬・開発におけるバイオマーカーの利用
  • 新しい診断の需要

付録

目次
Product Code: PHA0248

The global biomarkers market is expected to grow at a CAGR of 9.1% in the first half of the forecast period. In 2016, the largest sector of the market was biomarker discovery, which encompasses revenues for instruments and reagents, as well as the other costs associated with in-house biomarker research and development. This sector accounted for 49.3% of the global biomarkers market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 206-page report you will receive 66 tables and 59 figures- all unavailable elsewhere.

The 206-page report provides clear detailed insight into the global biomarkers market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Biomarkers Market forecasts from 2017-2027
  • This report also breaks down the revenue forecast for the global biomarkers market by Sector:
    • Biomarker Services
    • Biomarker Diagnostics
    • Biomarker Discovery
  • This report also breaks down the revenue forecast for the global biomarkers market by Discipline:
    • Genomics
    • Proteomics
    • Bioinformatics
    • Other
  • This report also breaks down the revenue forecast for the global biomarkers market by Therapeutic Indication:
    • Cancer
    • Cardiovascular Diseases
    • CNS,
    • Autoimmune Diseases
    • Other
  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • US
    • EU5 (further segmented into France, Germany, the UK, Spain and Italy)
    • Japan
    • China
    • India
    • Russia
    • Brazil
    • RoW

image1

  • Our study gives qualitative analysis of the biomarkers market. It includes a SWOT and STEP Analysis.
  • Our study discusses the selected leading companies that are the major players in the biomarkers industry. These companies are biomarker service providers, biomarker technology providers and biomarker diagnostic developers:
    • Quintiles IMS Holdings Inc
    • Laboratory Corporation of America Holdings
    • Parexel
    • Charles River Laboratories
    • ICON plc
    • WuXi PharmaTec
    • Caprion Proteomics
    • Proteome Sciences
    • Pacific Biomarkers
    • Oxford Gene Technology (OGT)
    • Worldwide Clinical Trials (WWC)
    • Agilent
    • AB SCIEX
    • QIAGEN
    • Axela Inc
    • Thermo Fisher Scientific
    • Quest Diagnostics
    • Myriad Genetics
    • Genomic Health
    • Critical Diagnostics
    • Epigenomics
    • MDxHealth (formerly OncoMethylome)
  • Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs:
    • Pfizer
    • Novartis
    • Roche Diagnostics
    • Ventana Medical Systems
    • Merck & Co.
    • Sanofi
    • GSK
    • Abbott Laboratories
    • AstraZeneca

Visiongain's study is intended for anyone requiring commercial analyses for the global biomarkers market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Biomarkers: World Market Overview
  • 1.2 Chapter Breakdown
  • 1.3 Research and Analysis Methods
  • 1.4 Market Definition, 2016

2. An Introduction to Biomarkers

  • 2.1 Definition of a Biomarker
    • 2.1.1 A Brief History of Biomarkers
    • 2.1.2 The Importance of Biomarkers
  • 2.2 Biomarker Discovery and Validation
  • 2.3 Uses of Biomarkers
    • 2.3.1 Assessing Drug Efficacy
    • 2.3.2 Assessing Drug Safety
    • 2.3.3 Companion Diagnostics
    • 2.3.3.1 CLIA vs. FDA Approval
    • 2.3.4 Therapeutic Importance of Biomarkers
    • 2.3.5 Imaging Biomarkers
      • 2.3.5.1 Imaging Biomarkers in Clinical Trials
  • 2.4 Biomarkers and Personalised Medicine
  • 2.5 Biomarker Discovery
    • 2.5.1 Genomics
      • 2.5.1.1 Pharmacogenomics
    • 2.5.2 Proteomics
    • 2.5.3 Metabolomics

3. The World Biomarkers Market, 2016-2027

  • 3.1 The World Biomarkers Market, 2016
    • 3.1.1 The World Biomarkers Market by Sector, 2016
    • 3.1.2 The World Biomarkers Market by Discipline, 2016
  • 3.2 The World Biomarkers Market: Overall Revenue Forecast, 2016-2027
    • 3.2.1 Lack of Investment and Reimbursement Issues May Restrain Market
  • 3.3 The World Biomarker Discovery Submarket, 2016
    • 3.3.1 The World Biomarker Discovery Submarket: Revenue Forecast 2016-2027
  • 3.4 The World Biomarker Diagnostics Submarket, 2016
    • 3.4.1 The World Biomarker Diagnostics Submarket: Revenue Forecast, 2017-2027
  • 3.5 The World Biomarker Services Submarket, 2016
    • 3.5.1 The World Biomarker Services Submarket: Revenue Forecast, 2016-2027
  • 3.6 The World Biomarkers Market: Overall Revenue Forecast by Discipline, 2016-2027
    • 3.6.1 The Genomics Submarket: Revenue Forecast, 2016-2027
      • 3.6.1.1 Next Generation Sequencing to Drive Growth
      • 3.6.1.2 Increased Focus on Genomic Research in China
      • 3.6.1.3 Application in Cardiovascular Disease
    • 3.6.2 The Proteomics Submarket: Revenue Forecast, 2016-2027
      • 3.6.2.1 Advances in Detection Technology Will Drive Market
    • 3.6.3 The Bioinformatics Submarket: Revenue Forecast, 2016-2027
      • 3.6.3.1 Market to Gather Pace with New Tools and Software in Pipeline
  • 3.7 Growth in Key Biomarker Disciplines, 2016-2027

4. Leading Indications for Biomarker Discovery and Development, 2016-2027

  • 4.1 The World Biomarkers Market by Indication, 2016
    • 4.1.1 Class of biomarkers
    • 4.1.2 Pharmacodynamic Biomarkers
  • 4.2 The World Biomarkers Market: Overall Revenue Forecast by Indication, 2016-2027
  • 4.3 Cancer Biomarker Market
    • 4.3.1 A Brief History of Cancer Biomarker Research
    • 4.3.2 The Current State of Cancer Biomarker Research
    • 4.3.3 Companion Diagnostics for Cancer
    • 4.3.4 Initiatives in Cancer Biomarker Research
      • 4.3.4.1 Cancer Genome Atlas
      • 4.3.4.2 The Early Detection Research Network
    • 4.3.5 Many Cancer Diagnostics Are Reaching the Market
    • 4.3.6 Opportunities and Challenges for Cancer Biomarkers
      • 4.3.6.1 Prostate Cancer: The Search for Urine Biomarkers
      • 4.3.6.2 Lung Cancer: High Biomarker Owing to Disease Prevalence
    • 4.3.7 Cancer Biomarker Submarket: Revenue Forecast, 2016-2027
  • 4.4 Cardiovascular Disease Biomarker Submarket 2016
    • 4.4.1 A Brief History of Cardiovascular Biomarker Research
    • 4.4.2 The Current State of Cardiovascular Disease Biomarker Research
    • 4.4.3 Cardiovascular Disease Diagnostics
      • 4.4.3.1 Roche Troponin Test Approved by FDA
    • 4.4.4 Collaborations in Cardiac Biomarker Research
      • 4.4.4.1 Bayer Health Extends Collaboration with Broad Institute and Harvard
      • 4.4.4.2 Singulex Inc Collaboration with University of Manchester
    • 4.4.5 The Future of Cardiovascular Biomarker Research
    • 4.4.6 Cardiovascular Disease Biomarker Submarket: Revenue Forecast, 2016-2027
  • 4.5 CNS Diseases Biomarker Submarket, 2016
    • 4.5.1 The Current State of CNS Disease Biomarker Research
    • 4.5.2 Initiatives in CNS Disease Biomarker Research
    • 4.5.3 Biomarker-Based Diagnostics for CNS Diseases
      • 4.5.3.1 ADtect (DiaGenic)
      • 4.5.3.2 Pittsburgh Compound B (PIB) (GE Healthcare)
      • 4.5.3.3 Florbetapir F18 (18F-AV-45) (Eli Lilly)
      • 4.5.3.4 Flutemetamol (GE Healthcare)
      • 4.5.3.5 Florbetaben (Piramal Imaging)
    • 4.5.4 CSF Biomarkers
    • 4.5.5 Alzheimer's Disease: Beyond Amyloid Beta
      • 4.5.5.1 New Criteria and Guidelines to Diagnose Alzheimer's Disease
    • 4.5.6 Multiple Sclerosis: Search for Disease Biomarker
    • 4.5.7 Parkinson's Disease: Effective Biomarker Yet to be Discovered
      • 4.5.7.1 Fluid-Based Biomarker Discovery
    • 4.5.8 CNS Diseases Biomarker Submarket: Revenue Forecast, 2016-2027
  • 4.6 Autoimmune Disease Biomarker Submarket, 2016
    • 4.6.1 Research Initiatives in Biomarker Research for Autoimmune Disease
    • 4.6.2 Marketed Biomarker Diagnostic Tests for Autoimmune Disease
      • 4.6.2.1 Ventra DA - Myraid Genetics
      • 4.6.2.2 NavigAID SSc - Protagen AG
      • 4.6.2.3 Autoimmune Thyroid Disease Tests - Thermo Fischer
    • 4.6.3 Increasing consolidation within the market
      • 4.6.3.1 Merck, Pfizer and Broad Institute Collaborate on biomarkers For Autoimmune Disorders
      • 4.6.3.2 Protagen AG and Qiagen on Protein Based Companion Diagnostics
    • 4.6.4 Autoimmune Diseases Biomarker Submarket: Revenue Forecast, 2016-2027
  • 4.7 Growth in Key Biomarker Indications, 2016-2027

5. Leading National Biomarker Markets, 2017-2027

  • 5.1 The World Biomarkers Market: Regional Breakdown, 2016
  • 5.2 The World Biomarkers Market: Regional Forecast, 2016-2027
  • 5.3 US Biomarkers Market, 2016
    • 5.3.1 FDA - New Draft Guidance on Companion Diagnostics
    • 5.3.2 FDA major shift in regulation of laboratory developed tests
    • 5.3.3 The US Biomarker Market: Revenue Forecast, 2016-2027
  • 5.4 EU5 Biomarker Markets, 2016
    • 5.4.1 EMA - New Draft Guidance on Companion Diagnostics
    • 5.4.2 EMA - New Draft Guidance on Alzheimer's Treatment
    • 5.4.3 EU5 Biomarker Markets: Revenue Forecasts, 2016-2027
    • 5.4.4 Germany Biomarker Market, 2016
      • 5.4.4.1 Government initiatives: CancerMark Project
      • 5.4.4.2 Germany: Biomarker Market Revenue Forecast, 2017-2027
    • 5.4.5 France Biomarker Market, 2016
      • 5.4.5.1 French Government Funds $17m Cancer Biomarker Effort
      • 5.4.5.2 Immunid Received Funding for Companion Diagnostic for Skin Cancer
      • 5.4.5.3 France: Biomarker Market Revenue Forecast, 2016-2027
    • 5.4.6 UK Biomarker Market, 2016
      • 5.4.6.1 Current stage of biomarker research in the UK
      • 5.4.6.2 100,000 Genomes Project
      • 5.4.6.3 £10 Million investment in Precision Panc project
      • 5.4.6.4 The UK Biomarker Market: Revenue Forecast, 2017-2027
    • 5.4.7 Spain Biomarker Market, 2016
      • 5.4.7.1 Spain: Biomarker Market Revenue Forecast, 2016-2027
    • 5.4.8 Italy Biomarker Market, 2016
      • 5.4.8.1 Italian Government Initiatives on Genomics
      • 5.4.8.2 Italy: Biomarker Market Revenue Forecast, 2017-2027
  • 5.5 Japan Biomarker Market, 2016
    • 5.5.1 PMDA - Guidance on Companion Diagnostics
    • 5.5.2 Japan: Biomarker Market Revenue Forecast, 2017-2027
  • 5.6 China Biomarker Market, 2016
    • 5.6.1 Expanding Economy Driving Biotechnology in China
    • 5.6.2 Companies Entering the Chinese Market
    • 5.6.3 China: Biomarker Market Revenue Forecast, 2017-2027
  • 5.7 India Biomarker Market, 2016
    • 5.7.1 GenomeAsia 100K
    • 5.7.2 New cancer institute funded by Indian Government
    • 5.7.3 India: Biomarker Market Revenue Forecast, 2017-2027
  • 5.8 Russia Biomarker Market, 2016
    • 5.8.1 Russia: Biomarker Market Revenue Forecast, 2017-2027
  • 5.9 Brazil Biomarker Market, 2016
    • 5.9.1 Brazil: Biomarker Market Revenue Forecast, 2017-2027
  • 5.10 RoW Biomarker Market, 2016

6. Biomarker Industry Trends, 2017-2027

  • 6.1 Strengths and Weaknesses of the Biomarkers Market, 2016
  • 6.2 Opportunities and Threats in the Biomarkers Market, 2017-2027
  • 6.3 STEP Analysis of The World Biomarkers Market
  • 6.4 Social Factors
    • 6.4.1 Patient Stratification: Striving Towards Personalised Medicine
    • 6.4.2 Biomarker Hype May Not Always Lead to New Discoveries
    • 6.4.3 Growing Emphasis on Oncology for Companies
  • 6.5 Technological Factors
    • 6.5.1 Decreasing Size, Increasing Sensitivity
      • 6.5.1.1 ABT Molecular Imaging
    • 6.5.2 The Need for More-Efficient Data Storage
  • 6.6 Economic Factors
    • 6.6.1 Biomarkers: Cutting the Cost of Drug Development
      • 6.6.1.1 Toxicity Biomarkers: Aiming to Reduce Clinical Drug Failures
    • 6.6.2 High Cost of Technology: Potential Barrier to Entry for Start-Ups
    • 6.6.3 Outsourcing Biomarker Discovery and Development
  • 6.7 Political Factors
    • 6.7.1 Public-Private Partnerships: Collaborative Efforts Aid Biomarker Discovery
    • 6.7.2 Improving Regulatory Guidelines to Speed Development
    • 6.7.3 Concerns Over Biomarker Patenting Hits Innovation
  • 6.8 Challenges in Developing Biomarkers
  • 6.9 Combining Drug and Diagnostic Development
  • 6.10 MicroRNA Biomarkers: A Prospective Target?
  • 6.11 Big Pharma and Biomarkers
    • 6.11.1 Pfizer
    • 6.11.2 Novartis
    • 6.11.3 Merck & Co.
    • 6.11.4 Sanofi
    • 6.11.5 Roche
      • 6.11.5.1 Roche Diagnostics
      • 6.11.5.2 Ventana Medical Systems
    • 6.11.6 GSK
    • 6.11.7 AstraZeneca
    • 6.11.8 Abbott Laboratories

7. Leading Companies in the Biomarkers Market, 2016

  • 7.1 Biomarker Service Providers
    • 7.1.1 Global CROs and Biomarkers
      • 7.1.1.1 Not All Global CROs Are Investing in Biomarkers
    • 7.1.2 Quintiles IMS Holdings Inc
      • 7.1.2.1 Quintiles and IMS Health Merger
    • 7.1.3 Laboratory Corporation of America Holdings
      • 7.1.3.1 LabCorp Diagnostics
      • 7.1.3.2 Covance Drug development
      • 7.1.3.3 Companion and Complimentary Diagnostics Launched for Cancer in 2016
    • 7.1.4 Parexel
    • 7.1.5 Charles River Laboratories
    • 7.1.6 ICON plc
    • 7.1.7 WuXi PharmaTec
    • 7.1.8 Caprion Proteomics
    • 7.1.9 Proteome Sciences
    • 7.1.10 Pacific Biomarkers
    • 7.1.11 Oxford Gene Technology
    • 7.1.12 Worldwide Clinical Trials
  • 7.2 Biomarker Technology Providers
    • 7.2.1 Agilent
      • 7.2.1.1 Diagnostics and Biomarker Assays
      • 7.2.1.2 Growing Asian Markets: Focus on South Korea
    • 7.2.2 AB SCIEX
      • 7.2.2.1 Partnership with Illumina, OneOmics project
    • 7.2.3 QIAGEN
    • 7.2.4 Axela
    • 7.2.5 Thermo Fisher Scientific
      • 7.2.5.1 Strategic Acquisitions
      • 7.2.5.2 Research Collaborations
      • 7.2.5.3 Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Centre
  • 7.3 Biomarker Diagnostic Developers
    • 7.3.1 Quest Diagnostics
      • 7.3.1.1 Acquisition of Med Fusion and ClearPoint Diagnostics
      • 7.3.1.2 Q2 Solutions, Join Venture Between Quest Diagnostics and Quintiles IMS Holdings Inc
    • 7.3.2 Myriad Genetics
      • 7.3.2.1 Pipeline
      • 7.3.2.2 BRACAnalysis Gains Approval as Companion Diagnostic
      • 7.3.2.3 Strategic Acquisitions
      • 7.3.2.4 Myriad RBM
    • 7.3.3 Genomic Health
      • 7.3.3.1 Collaborations with Epic Sciences and Biocartis
    • 7.3.4 Critical Diagnostics
    • 7.3.5 Epigenomics
      • 7.3.5.1 Diagnostic Product Portfolio
    • 7.3.6 MDxHealth
      • 7.3.6.1 Diagnostic Product Portfolio and Pipeline

8. Conclusions

  • 8.1 State of the World Biomarkers Market in 2016
  • 8.2 Growth in the World Biomarkers Market, 2017-2027
    • 8.2.1 Dominance of Leading Western Markets
  • 8.3 The Use of Biomarkers in Drug Discovery and Development
  • 8.4 Demand for New Diagnostics

Appendices

  • Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Figures

  • Figure 2.1 Definitions of a Biomarker, 2016
  • Figure 2.2 The Biomarker Discovery and Validation Process, 2016
  • Figure 3.1 World Biomarkers Market: Market Shares (%) by Sector, 2016
  • Figure 3.2 World Biomarkers Market: Market Shares (%) by Discipline, 2016
  • Figure 3.3 World Biomarkers Market: Drivers and Restraints, 2016-2027
  • Figure 3.4 World Biomarkers Market: Overall Market Forecast ($bn), 2016-2027
  • Figure 3.5 World Biomarkers Market: Market Shares (%) by Sector, 2021
  • Figure 3.6 World Biomarkers Market: Market Shares (%) by Sector, 2027
  • Figure 3.7 Biomarker Discovery Submarket: Drivers and Restraints, 2017-2027
  • Figure 3.8 Biomarker Discovery Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 3.9 Biomarker Diagnostics Submarket: Revenue Forecast ($bn), 2017-2027
  • Figure 3.10 Biomarker Diagnostics Submarket: Drivers and Restraints, 2017-2027
  • Figure 3.11 Biomarker Services Submarket: Drivers and Restraints, 2016-2027
  • Figure 3.12 Biomarker Services Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 3.13 Genomics Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 3.14 Genomics Submarket: Drivers and Restraints, 2016-2027
  • Figure 3.15 Proteomics Submarket: Drivers and Restraints, 2017-2027
  • Figure 3.16 Proteomics Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 3.17 Bioinformatics Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 3.18 Bioinformatics Submarket: Drivers and Restraints, 2016-2027
  • Figure 3.19 World Biomarkers Market: Market Shares (%) by Discipline, 2021
  • Figure 3.20 World Biomarkers Market: Market Shares (%) by Discipline, 2027
  • Figure 4.1 World Biomarkers Market: Market Share (%) by Indication, 2016
  • Figure 4.2 Pharmacodynamic Biomarkers in Drug Labelling by Indication
  • Figure 4.3 Cancer Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 4.4 Cardiovascular Disease Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 4.5 CNS Diseases Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 4.6 CNS Diseases Submarket: Revenue Forecast ($bn), 2016-2027
  • Figure 4.7 World Biomarkers Market: Market Share (%) by Indication, 2021
  • Figure 4.8 World Biomarkers Market: Market Shares (%) by Indication, 2027
  • Figure 5.1 World Biomarkers Market: Market Shares (%) by Country, 2016
  • Figure 5.2 World Biomarkers Market: Market Shares (%) by Country, 2021
  • Figure 5.3 World Biomarkers Market: Market Shares (%) by Country, 2027
  • Figure 5.4 US Biomarkers Market: Revenue Forecast ($bn), 2017-2027
  • Figure 5.5 Top 5 EU Biomarker Markets: Market Share (%) by Country, 2016
  • Figure 5.6 Top Five EU Biomarker Markets: Revenue Forecasts ($bn), 2017-2027
  • Figure 5.7 Germany: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.8 France: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.9 UK Biomarker Market: Revenue Forecast ($bn), 2017-2027
  • Figure 5.10 Spain: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.11 Italy: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.12 Japan Biomarker Market: Revenue Forecast ($bn), 2017-2027
  • Figure 5.13 China: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.14 India: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.15 Russia: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.16 Brazil: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 5.17 RoW: Biomarker Market Revenue Forecast ($bn), 2017-2027
  • Figure 6.1 US Cancer Deaths by Tumour Type, 2016
  • Figure 6.2 Average Cost of Sequencing the Human Genome ($mn), 2005-2015
  • Figure 7.1 Laboratory Corporation of America: Revenue by Sector ($bn), 2015-2016
  • Figure 7.2 Proteome Sciences: Revenue ($mn), 2015-2016
  • Figure 7.3 Myriad Genetics: Market Shares by Molecular Diagnostic Product (%), 2016
  • Figure 7.4 Genomic Health: Product Revenue ($mn), 2015-2016
  • Figure 7.5 Epigenomics Revenue ($mn), 2016-2017
  • Figure 7.6 MDxHealth: Revenue by Source ($mn), 2015-2016
  • Figure 8.1 World Biomarkers Market: Revenues ($bn) by Sector, 2016, 2021 and 2027
  • Figure 8.2 World Biomarkers Market: Revenues ($bn) by Discipline, 2016, 2021 and 2027
  • Figure 8.3 World Biomarkers Market: Revenues ($bn) by Disease, 2016, 2021 and 2027
  • Figure 8.4 World Biomarkers Market: Revenues ($bn) by Country, 2016, 2021 and 2027

List of Tables

  • Table 2.1 Selected Drugs with Pharmacogenomic Biomarkers Listed on their Labels, 2016
  • Table 2.2 Selected Clinically-Relevant Cancer Biomarkers, 2016
  • Table 2.3 Technologies and Platforms for Biomarker Research, 2016
  • Table 3.1 World Biomarkers Market: Revenue ($bn) and Market Shares (%) by Sector, 2016
  • Table 3.2 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Discipline, 2016
  • Table 3.3 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Sector, 2016-2027
  • Table 3.4 World Biomarkers Market: Market Shares (%) by Sector, 2016, 2021, 2027
  • Table 3.5 Biomarker Discovery Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 3.6 Biomarker Diagnostics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 3.7 Biomarker Services Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 3.8 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Discipline, 2016-2027
  • Table 3.9 Genomics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 3.10 Selected Producers of Single-Molecule Sequencing Technologies, 2016
  • Table 3.11 Proteomics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 3.12 Bioinformatics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 3.13 World Biomarker Market: Market Shares (%) by Discipline, 2016, 2021, 2027
  • Table 4.1 World Biomarkers Market: Market Share (%) by Indication, 2016
  • Table 4.2 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Indication, 2016-2027
  • Table 4.3 Selected Marketed Biomarker-Based Cancer Diagnostics, 2016
  • Table 4.4 Selected ALK Inhibitors in Development for Lung Cancer, 2016
  • Table 4.5 Cancer Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 4.6 Cardiovascular Disease Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 4.7 Research Collaborations in CNS Biomarker Research
  • Table 4.8 CNS Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 4.9 Autoimmune Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2016-2027
  • Table 4.10 World Biomarkers Market: Market Share (%) by Indication, 2016, 2021, 2027
  • Table 5.1 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Country, 2016
  • Table 5.2 World Biomarkers Market: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2017-2027
  • Table 5.3 World Biomarkers Market: Market Shares (%) by Country, 2016, 2021, 2027
  • Table 5.4 US Biomarkers Market: Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.5 Top 5 EU Biomarker Markets: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2016
  • Table 5.6 Top Five EU Biomarkers Markets: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2017-2027
  • Table 5.7 Germany: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.8 France: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.8 Germany: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.9 UK Biomarker Market: Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.10 Spain: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.11 Italy: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.12 Japan: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.13 China: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.14 India: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.15 Russia: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.16 Brazil: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 5.17 RoW: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2017-2027
  • Table 6.1 World Biomarkers Market: Strengths and Weaknesses, 2017-2027
  • Table 6.2 World Biomarkers Market: Opportunities and Threats, 2017-2027
  • Table 6.3 World Biomarkers Market: STEP Analysis, 2017-2027
  • Table 6.4 US Cancer Deaths by Tumour Type, 2016
  • Table 6.5 Selected Cancer Therapies Approved with a Biomarker, 2016
  • Table 6.6 PSTC Biomarkers in Development, 2016
  • Table 6.7 Average Cost of Sequencing the Human Genome: Revenue Forecast ($m, AGR %, CAGR %), 2005-2015
  • Table 6.8 IMI-Funded Biomarker Projects
  • Table 6.9 Drug Discovery Outsourcing: Overall Market and Subsector Forecast ($bn, AGR %, CAGR %), 2016, 2021 & 2027
  • Table 7.1 Laboratory Corporation of America: Revenue by Sector ($bn) 2015-2016
  • Table 7.2 Proteome Sciences: Revenue ($mn), 2015-2016
  • Table 7.3 Myriad Genetics: Biomarker Product Portfolio, 2016
  • Table 7.4 Company Revenue by Sector ($mn), 2016
  • Table 7.5 Myriad Genetics: Diagnostic Pipeline, 2016
  • Table 7.6 Genomic Health: Revenue by Division ($bn), 2015-2016
  • Table 7.7 Epigenomics: Revenue and Market Shares by Sector ($mn), 2015 -2016
  • Table 7.8 MDx Health: Revenue by Source ($mn), 2015-2016
  • Table 7.9 MDxHealth: Pipeline, 2016
  • Table 8.1 World Biomarkers Market: Revenues ($bn, CAGR %, Market Share %) by Sector, 2016, 2021 and 2027
  • Table 8.2 World Biomarkers Market: Revenues ($bn, CAGR %) by Discipline, 2016, 2021 and 2027
  • Table 8.3 World Biomarkers Market: Revenues ($bn, CAGR %) by Disease, 2016, 20121 and 2027
  • Table 8.4 World Biomarkers Market: Revenues ($bn, CAGR %) by Country, 2016, 2021 and 2027

Companies Listed

  • 454 Life Sciences (a subsidiary of Roche)
  • AB SCIEX
  • Abbott Laboratories
  • Abbott Molecular
  • Abcodia
  • ABT Molecular Imaging
  • ACS Biomarker
  • Advanced Cell Diagnostics (ACD)
  • Advion Bioanalytical Labs (part of Quintiles)
  • Affymetrix
  • Agendia
  • Agilent
  • Alacris Theranostics
  • Alere
  • Amarantus BioSciences
  • Amgen
  • Applied Biosystems (part of Life Technologies)
  • Aptiv Solutions
  • Arctic Partners
  • ARIAD Pharmaceuticals
  • Ariana Pharma
  • Arizona State University
  • Arrayit
  • ARUP Laboratories
  • AstraZeneca
  • Athena Diagnostics (a subsidiary of Quest Diagnostics)
  • Atherotech Diagnostics Lab
  • Aushon Biosystems
  • Axela Inc
  • Bayer
  • Belfer Institute for Applied Cancer Science [US]
  • Berkeley HeartLab (a subsidiary of Quest Diagnostics)
  • BG Medicine
  • BGI (formerly Beijing Genomics Institute)
  • Biofortis
  • Biosoft
  • BRAHMS (part of Thermo Fisher Scientific)
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • Cancer Research Technology
  • Caprion Proteomics
  • CBC (Comprehensive Biomarker Centre GmbH)
  • Celera (part of Quest Diagnostics)
  • Celgene
  • Cell Signaling Technology
  • Celldex Therapeutics
  • Cephalon (part of Teva)
  • Charles River Laboratories
  • Chronix Biomedical
  • Chugai Pharmaceutical
  • Ciphergen Biosystems
  • Clarient Diagnostic Services
  • Cleveland HeartLab
  • Clinigene International
  • Comprehensive Biomarker Center (formerly Febit)
  • Covance
  • Crelux
  • Critical Diagnostics
  • Critical Path Institute (C-Path) [US]
  • CTI Biotech
  • Daiichi Sankyo
  • Dako (now part of Agilent)
  • Dana-Farber Cancer Institute [US]
  • Danaher
  • DaVita Labs
  • DiaGenic
  • Durin Technologies
  • DxS (now part of QIAGEN)
  • EKO Diagnostic
  • Eli Lilly and Co.
  • Epic Sciences
  • Epigenomics
  • Epistem
  • EQT
  • Evotec
  • Exact Sciences
  • Exiqon
  • Exonhit
  • Ezose Sciences (part of Shionogi)
  • FEI Company
  • Foundation Medicine
  • Fujirebio Diagnostics
  • GE Healthcare
  • Genetic Technologies
  • Geneva Bioinformatics (GeneBio)
  • Genomic Health
  • GenWay Biotech
  • Great Point Partners
  • GSK
  • HD Biosciences
  • Health Diagnostic Laboratory
  • HealthLinx
  • Helicos BioSciences
  • Hewlett-Packard
  • HTG Molecular Diagnostics
  • ICON Plc
  • Illumina
  • ImmunId
  • Insight Genetics
  • Institute of Pathology Heidelberg (IPH)
  • Integrated Diagnostics
  • Ipsen
  • Ipsogen (a subsidiary of QIAGEN)
  • Isogen Life Science
  • Johnson & Johnson (J&J)
  • KU Leuven (University of Leuven)
  • LabCorp
  • Life Technologies
  • LightArray Biotech
  • M2Gen
  • Mayo Clinic [US]
  • Mayo Collaborative Services
  • MDxHealth
  • Medical Research Council [UK]
  • MediMedia Pharma Solutions
  • Memorial Sloan-Kettering Cancer Center [US]
  • Merck & Co.
  • Merck KGaA
  • Metabolon
  • Michael J Fox Foundation
  • Myriad Genetics
  • Myriad RBM (formerly Rules-Based Medicine, part of Myriad Genetics)
  • National Academy of Sciences (NAS) [US]
  • Nephromics
  • Novartis
  • Novartis Molecular Diagnostics (part of Novartis)
  • NovioGendix
  • Oncoimmune
  • Oncomedics
  • OpGen
  • OPKO Health
  • Orion Genomics
  • Oxford Cancer Biomarkers
  • Oxford Gene Technology
  • Pacific Biomarkers
  • Pacific Biosciences
  • Panomics (now part of Affymetrix)
  • Parexel
  • Patheon
  • Pathwork Diagnostics
  • Personal Genome Diagnostics
  • Pfizer
  • Pierre Fabre
  • PLUS Diagnostics
  • PMDA
  • Power3 Medical Products
  • PPD
  • Predictive Biosciences
  • Prometheus Laboratories
  • ProtagenAG
  • Proteome Sciences
  • QIAGEN
  • QLIDA Diagnostics
  • Quanterix
  • Quanticel Pharmaceuticals
  • Quest Diagnostics
  • Quintiles
  • Quintiles IMS Holdings Inc
  • Randox Laboratories
  • Randox Laboratories
  • Roche
  • SABiosciences (now part of QIAGEN)
  • Sandor Proteomic
  • Sanger Institute
  • Sanofi
  • Santaris Pharma
  • Servier
  • Shionogi
  • Siemens
  • Siemens Healthcare
  • Singulex Inc
  • Sividion Diagnostics
  • SMA Foundation [US]
  • Stemina Biomarker Discovery
  • Sysmex
  • Technology Strategy Board (TSB) [UK]
  • Teva Pharmaceutical Industries
  • Thallion Pharmaceuticals
  • The Biomarkers Consortium
  • Thermo Fisher Sciences
  • Thermo Fisher Scientific
  • Transgene
  • Trans-Hit Biomarkers
  • Tufts Center for the Study of Drug Development
  • Ventana Medical Systems
  • Vertex Pharmaceuticals
  • WaferGen
  • Warnex
  • Worldwide Clinical Trials
  • WuXi AppTec
  • Wuxi Pharmatech
  • Xcovery

List of Organizations Mentioned in the Report

  • American College of Cardiology Foundation (ACCF)
  • American Heart Association (AHA)
  • Association for Molecular Pathology (AMP) [US]
  • British Heart Foundation [UK]
  • Broad Institute [US]
  • Cancer Research UK
  • Centers for Medicare and Medicaid Services (CMS) [US]
  • Chinese State Food and Drug Administration (SFDA)
  • Commonwealth Scientific and Industrial Research Organisation (CSIRO) [Australia]
  • EMA (European Medicines Agency)
  • ETH Zurich
  • European Commission
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Medicines Agency (EMA)
  • European Stroke Research Network for Hypothermia (Euro-HYP)
  • Food and Drug Administration (FDA) [US]
  • Hirosaki University
  • Human Proteome Organisation (HUPO)
  • International Cancer Genome Consortium (ICGC)
  • Les entreprises du médicament (LEEM) [France]
  • Malmö University
  • Massachusetts General Hospital
  • Max Planck Institute for Molecular Genetics [Germany]
  • National Academy of Sciences
  • National Cancer Institute (NCI) [US]
  • National Health Service (NHS) [UK]
  • National Human Genome Research Institute (NHGRI) [US]
  • National Institute for Health and Clinical Excellence (NICE) [UK]
  • National Institute of Allergy and Infectious Diseases (NIAID) [US]
  • National Institute on Aging (NIA) [US]
  • National Jewish Health [US]
  • Newcastle University [UK]
  • NIH (National Institute of Health)
  • Oslo University Hospital
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
  • Predictive Safety Testing Consortium (PSTC) [US]
  • Shanghai Jiao Tong University
  • Stanford University
  • State Food and Drug Administration (SFDA) [China]
  • Technion-Israel Institute of Technology
  • University of Alabama
  • University of Medicine and Dentistry of New Jersey (UMDNJ)
  • University of Oslo
  • University of Turku
  • University of Washington
  • Wellcome Trust Sanger Institute [UK]
  • World Health Organization (WHO)
Back to Top